Amy Comander, MD
Director, Breast Oncology and Cancer Survivorship, Mass General Cancer Center
Highlights
- Speaker, 2025 Conference on Metastatic Breast Cancer
- Breast oncologist at the Massachusetts General Hospital Cancer Center
- Instructor in medicine at Harvard Medical School
- Board member of the Ellie Fund
Amy Comander, MD, is a breast oncologist at the Massachusetts General Hospital Cancer Center, where she serves as director of breast oncology and cancer survivorship at the Mass General Cancer Center in Waltham and Newton-Wellesley Hospital, as well as medical director of the Mass General Cancer Center in Waltham.
Amy also directs the lifestyle medicine program at the Mass General Cancer Center, which is the first cancer center to establish a dedicated program in this field.
As an instructor in medicine at Harvard Medical School, Dr. Comander teaches medical students and residents about oncology and lifestyle medicine. With a focus on cancer survivorship and lifestyle medicine, she is committed to improving the quality of life, well-being, and outcomes for individuals with cancer through lifestyle interventions, including exercise, diet, and mind-body approaches. She promotes healthy lifestyles for both patients undergoing treatment and those in survivorship.
A dedicated marathoner, Dr. Comander has run 11 consecutive Boston Marathons, motivated by her goal to enhance the lives of those with a cancer diagnosis. In collaboration with Beth Frates, MD, she launched “PAVING the Path to Wellness,” a 12-week lifestyle medicine-based survivorship program for women with breast cancer. Together with Dr. Frates and Michelle Tollefson, MD, she co-authored the “PAVING the Path to Wellness” workbook.
Dr. Comander also serves on the board of the Ellie Fund, a nonprofit providing services and support to women diagnosed with breast cancer in Massachusetts. She is a medical advisor to the nonprofit SurvivingBreastCancer.org and has served as a medical advisor to Oneinforty, an organization dedicated to educating Ashkenazi Jewish individuals about the one-in-40 chance of carrying a BRCA mutation.